ALLOZYNE logo
  • ALLOZYNE
  • Who We Are
    • Management
    • Board of Directors
    • Biociphering Advisory Board
    • Multiple Sclerosis Advisory Board
    • Key Opinion Leaders
  • What We Do
    • Research & Development
    • Platform
    • Pipeline
    • Therapeutic Focus
  • Investors

About ALLOZYNE

ALLOZYNE is rapidly developing a number of biologic therapeutics to serve the unmet medical need in various autoimmune and CNS indications.

Read more

Who We Are

ALLOZYNE is backed by a world renown scientific advisory board and highly experienced interferon advisory board.

Read more

What We Do

ALLOZYNE has developed and optimized two different biociphering methods that enable site specific bioconjugation of any peptide or protein.

Read more

Partnering

Partnering is an integral component of ALLOZYNE’s strategy to maximize the value of its technology, generate near- and mid-term revenue...

Read more
Latest News
  • Press Release: ALLOZYNE Announces Completion of Phase IA Trial by AZ01, A Long Lasting Interferon ß for Treatment of Relapsing Remitting Multiple Sclerosis
  • Press Release: ALLOZYNE Announces Positive Results From Phase 1B Trial of AZ01
More Categories
  • Partnering
  • Media
  • Events
  • Career Opportunities
  • Contact Us
  • Home
  • Who We Are
  • What We Do
  • Partnering
  • Investors
  • Media
  • Events
  • Careers
  • Contact

Copyright ©2012 Allozyne Inc. All Rights Reserved.